Oramed Pharmaceuticals Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nadav Kidron
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1185 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- May 1, 2007
- CIK
- 0001176309
- Website
- oramed.com
- Similar Companies
- Business
- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) develops and commercializes oral delivery solutions for peptide and protein therapeutics, primarily focused on oral insulin formulations for diabetes treatment. The company's core products and services include ORMD-0801, an oral insulin capsule in Phase 3 clinical trials for glycemic control in type 2 diabetes; ORMD-0901, an oral GLP-1 receptor agonist analog for obesity and diabetes management; and a proprietary Protein Oral Delivery (POD) technology platform enabling non-invasive administration of biologics such as peptides, proteins, and vaccines via oral capsules, which offers improved patient compliance over injections. ORamed also provides contract research and development services for oral drug delivery systems, targeting pharmaceutical companies seeking needle-free alternatives. Founded in 1991 and headquartered in Jerusalem, Israel, with operations extending to the United States through its subsidiary Oramed Pharmaceuticals Inc., the company operates in the biopharmaceutical industry, serving patients with metabolic diseases, endocrinologists, and global healthcare providers in North America, Europe, and Asia. Its pipeline emphasizes innovative gastrointestinal absorption enhancers and protease inhibitors to protect macromolecules from degradation, positioning it as a leader in oral peptide therapeutics. In the last 1-2 years, Oramed reported positive topline results from its Phase 3 T2D-003 trial of ORMD-0801 in September 2024, demonstrating statistically significant A1C reduction and advancing toward a New Drug Application submission to the FDA in 2025; entered a strategic licensing agreement with China's Zhejiang Hisun Pharmaceutical in 2024 for ORMD-0801 commercialization in Greater China; and expanded its obesity pipeline with ORMD-0901, initiating preclinical studies for semaglutide-based oral formulations amid surging demand for GLP-1 therapies. These developments underscore Oramed's shift toward late-stage commercialization and international partnerships, including ongoing U.S. regulatory engagements and manufacturing scale-up at its FDA-inspected facilities.
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & Akanda (NASDAQ:AKAN)
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
Head to Head Review: GN Store Nord (OTCMKTS:GNNDY) and Oramed Pharmaceuticals (NASDAQ:ORMP)
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average – Here’s Why
Comparing QuidelOrtho (NASDAQ:QDEL) & Oramed Pharmaceuticals (NASDAQ:ORMP)
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average – Time to Sell?
Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company
Oramed and Lifeward Announce Strategic Transaction
Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & GE HealthCare Technologies (NASDAQ:GEHC)
Oramed Pharmaceuticals: Scarred, Well-Capitalized, And Regrouping After Setback
Oramed Reports Fiscal Third Quarter 2025 Financial Results
ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
3 Micro-Cap Moonshots for Fearless Investors